Stock listing
NASDAQ:SPTX Seaport Therapeutics, Inc. Stock
Home listing (NASDAQ) of Seaport Therapeutics, Inc.
Follow Seaport Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:SPTX
$18.05 USD -0.26 (-1.4%)
Close on Nov 20, 2026
- Day range
- $17.41 – $18.83 USDNov 20, 2026
- Volume
- 284,271 sharesNov 20, 2026
- Market cap
- $966.2M USDAt the close on Nov 20, 2026 · price × 53.53M shares outstanding
- Traded on an average day
- $5.21M USDMedian day 192,796 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SPTX · Home | $18.05 USD | -0.26 (-1.4%) | 284,271 | $18.02 | $18.83 | $17.41 | $18.31 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SPTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $18.05 | -0.26 | -1.4% | $18.02 | $18.83 | $17.41 | 284,271 | |
| $18.31 | +0.14 | +0.8% | $18.19 | $19.12 | $17.84 | 683,621 | |
| $18.17 | -0.95 | -5.0% | $19.01 | $19.39 | $17.90 | 278,253 | |
| $19.12 | -0.86 | -4.3% | $19.70 | $20.15 | $18.62 | 387,017 | |
| $19.98 | -0.15 | -0.7% | $20.10 | $20.53 | $19.56 | 346,855 | |
| $20.13 | -1.18 | -5.5% | $20.99 | $21.35 | $19.94 | 228,588 | |
| $21.31 | -0.66 | -3.0% | $21.83 | $21.83 | $20.26 | 225,685 | |
| $21.97 | +0.045 | +0.2% | $22.00 | $22.23 | $21.05 | 301,047 | |
| $21.93 | +0.425 | +2.0% | $21.89 | $22.68 | $21.28 | 306,863 | |
| $21.50 | +1.11 | +5.4% | $20.85 | $21.75 | $19.77 | 227,029 | |
| $20.39 | -0.57 | -2.7% | $21.07 | $21.07 | $19.88 | 221,060 | |
| $20.96 | +0.76 | +3.8% | $21.61 | $21.76 | $20.02 | 336,175 | |
| $20.20 | +0.19 | +0.9% | $20.01 | $20.56 | $19.51 | 393,648 | |
| $20.01 | +0.41 | +2.1% | $19.68 | $21.07 | $19.13 | 527,902 | |
| $19.60 | -1.50 | -7.1% | $20.96 | $21.16 | $19.00 | 549,189 | |
| $21.10 | +0.72 | +3.5% | $20.71 | $22.09 | $20.48 | 272,147 | |
| $20.38 | -0.90 | -4.2% | $20.81 | $21.02 | $19.53 | 355,270 | |
| $21.28 | +0.45 | +2.2% | $21.00 | $22.05 | $20.73 | 219,054 | |
| $20.83 | +0.22 | +1.1% | $20.76 | $21.69 | $20.34 | 124,685 | |
| $20.61 | -0.15 | -0.7% | $20.72 | $20.89 | $19.99 | 164,566 | |
| $20.76 | +1.03 | +5.2% | $19.74 | $21.07 | $19.74 | 131,421 | |
| $19.73 | +0.45 | +2.3% | $19.27 | $20.13 | $18.00 | 134,583 | |
| $19.28 | +1.49 | +8.4% | $17.98 | $19.63 | $17.56 | 145,273 | |
| $17.79 | -0.04 | -0.2% | $17.83 | $18.12 | $17.47 | 145,736 | |
| $17.83 | +0.23 | +1.3% | $17.63 | $18.00 | $17.14 | 184,539 | |
| $17.60 | +0.92 | +5.5% | $16.82 | $17.89 | $16.61 | 164,911 | |
| $16.68 | +0.60 | +3.7% | $15.98 | $16.97 | $15.79 | 208,623 | |
| $16.08 | -1.07 | -6.2% | $17.08 | $17.62 | $16.03 | 227,202 | |
| $17.15 | -1.00 | -5.5% | $18.14 | $18.14 | $17.04 | 126,005 | |
| $18.15 | +0.24 | +1.3% | $18.00 | $18.79 | $17.89 | 171,206 | |
| $17.91 | -0.02 | -0.1% | $17.67 | $18.46 | $17.67 | 177,595 | |
| $17.93 | +0.56 | +3.2% | $17.28 | $18.29 | $17.07 | 249,080 | |
| $17.37 | -1.13 | -6.1% | $18.50 | $19.05 | $17.18 | 243,005 | |
| $18.50 | +0.08 | +0.4% | $18.42 | $18.90 | $17.52 | 172,570 | |
| $18.42 | -0.53 | -2.8% | $19.16 | $19.16 | $17.85 | 258,702 | |
| $18.95 | -1.22 | -6.0% | $20.12 | $20.71 | $18.37 | 330,192 | |
| $20.17 | +1.48 | +7.9% | $18.85 | $20.75 | $18.45 | 488,678 | |
| $18.69 | -0.95 | -4.8% | $19.46 | $19.80 | $18.57 | 288,869 | |
| $19.64 | -1.88 | -8.7% | $21.31 | $21.99 | $19.22 | 284,477 | |
| $21.52 | +0.40 | +1.9% | $22.20 | $22.44 | $21.45 | 192,796 | |
| $21.12 | -0.17 | -0.8% | $21.08 | $21.37 | $19.93 | 105,737 | |
| $21.29 | -1.10 | -4.9% | $22.12 | $23.07 | $21.03 | 179,279 | |
| $22.39 | +1.27 | +6.0% | $21.20 | $22.67 | $21.20 | 146,461 | |
| $21.12 | -0.27 | -1.3% | $21.46 | $21.94 | $20.28 | 234,265 | |
| $21.39 | -0.43 | -2.0% | $21.88 | $23.10 | $21.29 | 2,178,493 | |
| $21.82 | -0.32 | -1.4% | $22.46 | $23.14 | $21.10 | 205,613 | |
| $22.14 | -0.82 | -3.6% | $23.01 | $24.61 | $21.98 | 235,897 | |
| $22.96 | -1.74 | -7.0% | $24.56 | $24.95 | $22.63 | 158,970 | |
| $24.70 | +1.36 | +5.8% | $23.33 | $25.37 | $23.33 | 174,188 | |
| $23.34 | +0.06 | +0.3% | $23.39 | $24.36 | $23.00 | 134,166 | |
| $23.28 | +1.53 | +7.0% | $21.58 | $23.28 | $21.58 | 144,714 | |
| $21.75 | -2.31 | -9.6% | $24.14 | $25.52 | $21.73 | 316,780 | |
| $24.06 | -0.80 | -3.2% | $24.89 | $25.43 | $23.77 | 141,709 | |
| $24.86 | +0.57 | +2.3% | $24.03 | $25.00 | $23.63 | 104,337 | |
| $24.29 | -0.62 | -2.5% | $24.80 | $26.01 | $23.58 | 86,222 | |
| $24.91 | +1.30 | +5.5% | $23.66 | $25.21 | $23.65 | 156,427 | |
| $23.61 | -0.07 | -0.3% | $23.68 | $24.20 | $23.24 | 122,756 | |
| $23.68 | -0.36 | -1.5% | $24.14 | $26.47 | $23.01 | 117,846 | |
| $24.04 | -2.21 | -8.4% | $26.09 | $26.87 | $24.04 | 144,826 | |
| $26.25 | -1.59 | -5.7% | $27.84 | $28.38 | $26.06 | 128,656 | |
| $27.84 | +3.01 | +12.1% | $25.11 | $28.37 | $24.42 | 135,682 | |
| $24.83 | +0.75 | +3.1% | $24.25 | $25.42 | $24.25 | 85,792 | |
| $24.08 | -0.23 | -0.9% | $24.40 | $26.47 | $23.46 | 110,488 | |
| $24.31 | +0.275 | +1.1% | $23.81 | $25.12 | $23.78 | 83,149 | |
| $24.04 | -0.385 | -1.6% | $24.12 | $25.45 | $23.53 | 86,323 |
- Ticker
- NASDAQ:SPTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 2, 2026
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 40 slides
Latest news
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Nov 2, 2026
Closed $20.01 (+2.1%) on Nov 2, 2026
Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
Oct 28, 2026
Closed $20.38 (-4.2%) on Oct 28, 2026
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Oct 9, 2026
Closed $18.15 (+1.3%) on Oct 9, 2026
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Oct 7, 2026
Closed $17.93 (+3.2%) on Oct 7, 2026
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Oct 7, 2026
Closed $17.93 (+3.2%) on Oct 7, 2026
Seaport Therapeutics to Participate in September Investor Conferences
Sep 14, 2026
Closed $24.70 (+5.8%) on Sep 14, 2026
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Sep 9, 2026
Closed $21.75 (-9.6%) on Sep 9, 2026
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Aug 3, 2026
Closed $20.65 (+0.9%) on Aug 3, 2026
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Jun 9, 2026
Closed $17.66 (+9.0%) on Jun 9, 2026
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Jun 8, 2026
Closed $16.20 (-1.5%) on Jun 8, 2026
Seaport Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 14 in all · newest Nov 2, 2026 · oldest 2026
- Decks
- 6 decks · latest November 2026
Where Seaport Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SPTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:SPTX | BOATS | United States | USD |
Valuation
Price/book 2.4× against a median of 2.5×: 4th lowest of 8 Biotechnology companies shown. balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $675.8M USD
- P/E
- Not reported
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.72
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. · NASDAQ:SPTX | US$966.2M | US$675.8M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 0.72 |
| Inhibrx Biosciences, Inc. · NASDAQ:INBX | US$1.02B | US$1.09B | n/a | 546× | n/a | n/a | n/a | n/a | 1.89 |
| Duality Biotherapeutics, Inc. · HKEX:9606 | US$992.3M | US$609.0M | n/a | 4.8× | n/a | 4.6× | −170.8% | 0.3× | n/a |
| Peptron, Inc. · KRX:087010 | US$985.3M | US$948.0M | n/a | 211× | n/a | 10.2× | −342.2% | 0.2× | n/a |
| Omeros Corporation · NASDAQ:OMER | US$983.7M | US$920.3M | 10.0× | 12.4× | n/a | n/a | 132.3% | n/a | 1.64 |
| Everest Medicines Ltd. · HKEX:1952 | US$981.5M | US$1.00B | n/a | 2.8× | 183× | 1.3× | −2.2% | 0.4× | n/a |
| HBM Holdings Ltd. · HKEX:2142 | US$981.4M | US$711.5M | 10.7× | 4.5× | 8.6× | 2.4× | 57.8% | 0.2× | n/a |
| City Therapeutics, Inc. · NASDAQ:CTY | US$972.4M | US$802.8M | n/a | 59.2× | n/a | n/a | −431.4% | n/a | n/a |
| MoonLake Immunotherapeutics · NASDAQ:MLTX | US$942.1M | US$543.7M | n/a | n/a | n/a | 2.5× | n/a | 0.3× | 1.32 |
| Savara, Inc. · NASDAQ:SVRA | US$939.9M | US$840.4M | n/a | n/a | n/a | 8.7× | n/a | 0.3× | 1.42 |
| Metis TechBio Co., Ltd. Class H · HKEX:7666 | US$918.1M | US$487.6M | n/a | 223× | n/a | 2.0× | −373.2% | 0.0× | n/a |
| Median of the others | US$981.5M | US$821.6M | 10.4× | 35.8× | 95.9× | 2.5× | −170.8% | 0.3× | 1.53 |
Forecasts
7 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 37.13 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.75 · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Daphne Zohar | Founder, CEO & Board Member |
| Lauren White | Chief Financial Officer |
| Antony Loebel | Chief Medical Officer and President of Clinical Development |
| Eric Green | Chief Operating Officer |
| Lana Gladstein | General Counsel |
| Shannon Costello | Vice President, Communications |
| Michael Chen | Co-founder, Chief Scientific Officer |
| Steven Paul | Founder, Board Chair |
Board
| Director | Role |
|---|---|
| Bob Hombach | Board Member |
| Daphne Zohar | Founder, CEO & Board Member |
| David Wheadon | Board Member |
| Denice Torres | Board Member |
| Jason Pitts | Board Member |
| Jim Healy | Board Member |
| Sandi Peterson | Board Member |
| Sharon Mates | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 2, 2026 · Before open | +2.1% |
| Q2 2026 | Aug 3, 2026 · Before open | +0.9% |
| Q1 2026 | Jun 8, 2026 · Before open | −1.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 40 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 40 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 40 slides | September 2026 |
| Investor Presentation (September 2026) | Investor deck | 39 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 38 slides | August 2026 |
| Investor Presentation (June 2026) | Investor deck | 38 slides | June 2026 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: US$254.9M · US$18 a share · Goldman Sachs & Co. LLC +4 Dealers: Goldman Sachs & Co. LLC (co-lead), J.P. Morgan (co-lead), Leerink Partners (co-lead), Citigroup (co-lead), Stifel (co-lead) | May 1, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Apr 30, 2026.
- Price
- US$18.00 a share
- Shares offered
- 14,160,000 shares of common stock
- Offering size
- US$254.9 million
- Underwriters' option
- Up to 2,124,000 more shares
- Listing
- SPTX on the Nasdaq Global Select Market
- Underwriters
- Goldman Sachs & Co. LLC, J.P. Morgan, Leerink Partners, Citigroup, Stifel · In the order on the cover
- Shares delivered
- On or about May 4, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 21, 2025 |
| Filed publicly | Apr 10, 2026 |
| Amended once | Apr 27, 2026 |
| Shares registered with an exchange | Apr 28, 2026 |
| Declared effective by the SEC | Apr 30, 2026 |
| Final prospectus, with the price | May 1, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 1, 2026 |
| EFFECT · Notice that a registration is effective | Apr 30, 2026 |
| S-1MEF · Registration of more shares for the same offering | Apr 30, 2026 |
| CERT · Exchange's certificate of listing | Apr 30, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 28, 2026 |
| S-1/A · Registration statement, amended | Apr 27, 2026 |
| S-1 · Registration statement | Apr 10, 2026 |
| DRS/A · Draft registration statement, amended | Feb 27, 2026 |
| DRS/A · Draft registration statement, amended | Jan 29, 2026 |
| DRS · Draft registration statement | Nov 21, 2025 |
Open IPO · From the cover of the final prospectus (424B4) filed May 1, 2026
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 2, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 5, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
All 59 filings
Cap table
Built by 6ix from Seaport Therapeutics, Inc.’s releases · as of Oct 27, 2026
- Common shares
- 53,530,550
- Fully diluted
- 53,530,550
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 53,530,550 | Oct 27, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 27, 2026 | 53,530,550 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James Healy Other companies: BioAge Labs, Inc. (Director · Since at least Sep 25, 2024); Rapport Therapeutics, Inc. (Director · Since at least Jun 6, 2024); ArriVent BioPharma, Inc. (Director · Since at least Jan 25, 2024); Y mAbs Therapeutics (Director · Since at least Jun 12, 2019); CinCor Pharma Inc (Director · Jan 6, 2022 – Nov 28, 2022 · Past); Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); Coherus Oncology, Inc. (Director · May 22, 2019 – Jan 7, 2022 · Past); Natera, Inc. (Director · Sep 14, 2018 – Apr 25, 2025 · Past) | Director · Since at least Apr 30, 2026 |
| David E. Wheadon Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Supernus Pharmaceuticals, Inc. (Director · Since at least Jan 1, 2026); Vaxart, Inc. (Director · Since at least Aug 4, 2022); Sotera Health Company (Director · Since at least May 27, 2022); Karuna Therapeutics Inc (Director · Jun 15, 2022 – Mar 18, 2024 · Past); ChemoCentryx Inc. (Director · May 26, 2022 – Oct 20, 2022 · Past) | Director · Since at least Apr 30, 2026 |
| Denice Torres Other companies: Celldex Therapeutics, Inc. (Chief Executive Officer; The Ignited Company · Since at least Jun 5, 2025); Glaukos Corporation (Director · Since at least Mar 1, 2021); 2Seventy Bio Inc (Director · Oct 18, 2021 – May 13, 2025 · Past); Surface Oncology Inc (Director · Jul 6, 2021 – Jun 8, 2022 · Past); Karuna Therapeutics Inc (Director · Dec 22, 2020 – Mar 18, 2024 · Past); Bluebird bio Inc (Director · Aug 10, 2020 – Nov 11, 2021 · Past) | Board Member · Since at least Apr 30, 2026 |
| Robert J. Hombach Other companies: Henry Schein, Inc. (Director · Since at least Jan 29, 2025); Embecta Corp. (Director · Since at least Mar 20, 2022); BioMarin Pharmaceutical Inc. (Director · Since at least Sep 29, 2017); Aptinyx Inc (Director · Jun 20, 2018 – May 26, 2022 · Past); CarMax Inc (Director · Apr 1, 2018 – Jul 2, 2021 · Past); Baxalta Inc (EVP. CFO and COO · Jul 1, 2015 – Jun 3, 2016 · Past) | Director · Since at least Apr 30, 2026 |
| Steve Paul Other companies: Rapport Therapeutics, Inc. (Director · Since at least Jun 6, 2024); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 3, 2016 – Apr 1, 2022 · Past); Sigma-Aldrich Corp (Director · Nov 18, 2015 – Nov 18, 2015 · Past); Voyager Therapeutics, Inc. (Director · Nov 10, 2015 – Jun 3, 2021 · Past); Sage Therapeutics Inc (Director · Jul 1, 2015 – Jan 3, 2024 · Past) | Director · Since at least Apr 30, 2026 |
| Sandra E Peterson Other companies: Microsoft Corp. (Director · Since at least Dec 2, 2015); Zymergen Inc (Director · Apr 21, 2021 – Oct 19, 2022 · Past); Covetrus Inc (Director · Jun 10, 2020 – Oct 13, 2022 · Past); Johnson & Johnson (Exec VP, Group WW Chairman · Dec 1, 2012 – Feb 12, 2018 · Past); Dun & Bradstreet Holdings Inc. (Director · Mar 29, 2007 – Sep 11, 2015 · Past) | Director · Since at least Apr 30, 2026 |
| Atlantic S a r l General Other companies: Liftoff Mobile, Inc. (Director · Since at least Jun 4, 2026); Alkami Technology, Inc. (Director · Since at least Apr 13, 2021); Centessa Pharmaceuticals PLC (Director · Jun 22, 2023 – Jun 22, 2023 · Past); HireRight Holdings Corp (Director · Nov 16, 2022 – Jun 28, 2024 · Past) | Director · Since at least May 4, 2026 |
| Sharon Mates Other companies: PureTech Health PLC (Director · Since at least Apr 27, 2026); Benitec Biopharma Inc. (Director · Since at least Nov 3, 2025); Intra-Cellular Therapies Inc (Chairman and CEO, Director · Aug 29, 2013 – Apr 2, 2025 · Past) | Director · Since at least Apr 30, 2026 |
| Daphne Zohar Other companies: Adicet Bio, Inc. (Director · Jan 25, 2018 – Jan 25, 2018 · Past) | Founder, CEO & Board Member · Since at least Apr 30, 2026 |
| Antony Loebel | Chief Medical Officer · Since at least May 4, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Bob Hombach | Board Member · Since at least Jun 24, 2026 |
| Eric Green | Chief Operating Officer · Since at least Nov 4, 2026 |
| Jason Pitts | Board Member · Since at least Nov 5, 2026 |
| Jim Healy | Board Member · Since at least May 4, 2026 |
| Lana Gladstein | General Counsel · Since at least May 4, 2026 |
| Lauren White | Chief Financial Officer · Since at least May 4, 2026 |
| Michael Chen | Co-founder, Chief Scientific Officer · Since at least Apr 30, 2026 |
| Sandi Peterson | Board Member · Since at least Nov 5, 2026 |
| Shannon Costello | Vice President, Communications · Since at least Oct 9, 2026 |
| Steven Paul | Founder, Board Chair · Since at least May 4, 2026 |
Log in to ask 6ix AI your own questions about Seaport Therapeutics, Inc.